In vitro diagnostics firm QuidelOrtho beats Q3 revenue expectations

Quidelortho

05/11/2025 22:29

Overview

QuidelOrtho reports Q3 revenue of $700 mln, beating analysts' expectations

Adjusted EPS beats consensus, reflecting effective cost-savings initiatives

Company reports goodwill impairment charge of $701 mln, impacting GAAP net loss

Outlook

QuidelOrtho sees full-year 2025 revenue between $2.68 bln and $2.74 bln

Company expects full-year 2025 adjusted EBITDA of $585 mln to $605 mln

QuidelOrtho forecasts full-year 2025 adjusted EPS between $2.00 and $2.15

Result Drivers

REVENUE DECLINE - Total revenue decreased 4% due to lower COVID-19 and Donor Screening revenue

COST-SAVINGS INITIATIVES - Decreased operating expenses and improved adjusted EBITDA margin attributed to cost-savings measures

DEBT REFINANCING - Successful debt refinancing improved financial flexibility through better terms and reduced obligations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$699.9 mln
$664.96 mln (8 Analysts)
Q3 Adjusted EPS
Beat
$0.80
$0.46 (7 Analysts)
Q3 EPS
-$10.78
Q3 Net Income
-$733 mln
Q3 Basic EPS
-$10.78
Q3 Operating Income
-$704.8 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for QuidelOrtho Corp is $34.00, about 20.2% above its November 4 closing price of $27.13

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPn9KJl95a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)